Estrella Immunopharma nears completion of SPAC listing
The developer of T-cell cancer therapies is based in California, but says it ‘may be subject to risks’ due to its numerous China connections Key Takeaways: Estrella Immunopharma is nearing…
ESLA.US
Recent Articles
RELATED ARTICLES
-
Synagistics holds potential to enliven moribund Hong Kong SPAC market
7841.HK
- Stealthy eLong Power sneaks closer to U.S. listing
-
Geely flexes deal-making muscle as Lotus Technology nears listing finish line
LOT.US
-
ZG Group and Aquila aim to score Hong Kong’s first SPAC merger success
7836.HK
-
Sinking Burning Rock faces de-listing. But could privatization bid come first?
BNR.US
- CHINA BULLETIN: Services, Trade Send Positive Signals
- Sichuan Biokin chases Hong Kong listing after BSM drug deal
Discover hidden China stock gems in our weekly newsletter